Though trastuzumab, a humanized anti-HER2 monoclonal antibody approved for treating HER2-positive BC in 1998, acts as the first targeted therapeutic drug specific to BC targeting HER2 [54], its general resistance in the clinic has become a great challenge for targeted therapy. The gene discussed is ERBB2; the disease is breast cancer.